Is Pegasys Still Used for Hepatitis C Treatment?
Pegasys (peginterferon alfa-2a) is no longer a first-line treatment for hepatitis C virus (HCV) due to the dominance of direct-acting antivirals (DAAs) like sofosbuvir and glecaprevir/pibrentasvir, which cure over 95% of cases with 8-12 weeks of oral therapy and fewer side effects.[1] Guidelines from the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) recommend DAAs for all HCV genotypes, relegating interferon-based regimens like Pegasys to historical use.[2][3]
When Might Doctors Still Prescribe Pegasys?
Pegasys sees rare off-label or salvage use in specific cases, such as DAA treatment failures, decompensated cirrhosis, or resource-limited settings where DAAs are unavailable or unaffordable. It's sometimes combined with ribavirin for interferon-eligible patients intolerant to DAAs, but evidence shows inferior sustained virologic response (SVR) rates of 50-80% versus DAAs' 95%+.[4] In the U.S., prescriptions have dropped over 90% since 2014, per IQVIA data, though it's not fully discontinued.[5]
How Does Pegasys Compare to Modern DAA Options?
| Treatment | Cure Rate | Duration | Common Side Effects | Cost (U.S., approx.) |
|-----------|-----------|----------|---------------------|----------------------|
| Pegasys + ribavirin | 50-80% | 24-48 weeks (injections) | Flu-like symptoms, anemia, depression, thyroid issues | $20,000-$40,000/course |
| Epclusa (sofosbuvir/velpatasvir) | >95% | 12 weeks (pills) | Headache, fatigue (mild) | $25,000-$75,000 (varies by insurance) |
| Mavyret (glecaprevir/pibrentasvir) | >98% | 8 weeks (pills) | Few; mostly mild | $25,000-$30,000 |
DAAs target viral proteins directly, avoiding Pegasys's immune-stimulating mechanism, which caused high dropout rates (20-30%).[6]
Availability and Patent Status
Pegasys remains available worldwide from Roche/Genentech, with U.S. approval since 2002. Key patents expired in 2014-2018, enabling generics in some markets like India, but brand versions persist where demand lingers.[7] DrugPatentWatch.com lists no active U.S. Orange Book patents blocking generics, though low demand limits their entry.[7]
Patient Concerns and Access Issues
Patients report Pegasys's weekly injections and severe side effects as major barriers, driving shifts to DAAs. In low-income countries, WHO still lists it as an option due to DAA costs ($300+ generics vs. Pegasys at $1,000/course), but global eradication goals favor DAAs.[8] No major shortages reported, but consult a hepatologist for genotype-specific advice.
Sources:
[1] AASLD-IDSA HCV Guidance (2023) - https://www.hcvguidelines.org/
[2] EASL HCV Recommendations (2022) - https://easl.eu/publication/easl-recommendations-on-treatment-of-hepatitis-c-2022/
[3] NEJM Review on DAAs (2019)
[4] Lancet Gastroenterol Hepatol (2021)
[5] IQVIA National Prescription Audit
[6] FDA Label for Pegasys - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103964s525lbl.pdf
[7] DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/Pegasys
[8] WHO Hepatitis C Guidelines (2022) - https://www.who.int/publications/i/item/9789240051494